SCHEMBL6691092

SCHEMBL6691092

CC1(C)OB(c2cc(F)c(F)c(F)c2)OC1(C)C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPL P06858 13/20 0.50
LIPG Q9Y5X9 13/20 0.50
ROCK1 Q13464 1/20 0.39
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA9 Q16790 3/20 0.36
CA12 O43570 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
F11 P03951 1/20 0.35
P2RX7 Q99572 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22771042 0.88 LPL (0.44) LPLLIPGROCK1CA1CA2
SCHEMBL14956694 0.87 LPL (0.43) LPLLIPGROCK1CA1CA2
SCHEMBL12327213 0.87 LPL (0.43) LPLLIPGROCK1CA1CA2
SCHEMBL16655624 0.87 LPL (0.43) LPLLIPGROCK1CA1CA2
SCHEMBL26153570 0.85 LPL (0.48) LPLLIPGROCK1CA1CA2
SCHEMBL19804941 0.84 LPL (0.41) LPLLIPGROCK1CA1CA2
SCHEMBL14274294 0.84 LPL (0.41) LPLLIPGROCK1CA1CA2
SCHEMBL30129305 0.84 LPL (0.41) LPLLIPGROCK1CA1CA2
SCHEMBL16655990 0.84 LPL (0.41) LPLLIPGROCK1CA1CA2
SCHEMBL587558 0.83 LPL (0.47) LPLLIPGROCK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2026-05-19 US claimed
CN-117486916-B Synthesis method of 3,4, 5-trifluoro-phenylboronic acid 山东国邦药业有限公司 2024-04-12 CN claimed
CN-117486916-A Synthesis method of 3,4, 5-trifluoro-phenylboronic acid 山东国邦药业有限公司 2024-02-02 CN claimed
US-20220263102-A1 ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2022-08-18 US claimed
EP-3997748-A1 ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS LITRONIK Batterietechnologie GmbH (DE) 2022-05-18 EP claimed
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2026-05-19 US disclosed
WO-2025070482-A1 COMPOUND, LIGHT-EMITTING MATERIAL, AND ORGANIC LIGHT-EMITTING ELEMENT 株式会社Kyulux 2025-04-03 WO disclosed
US-20250026778-A1 GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR TIUMBIO CO., LTD. (KR) 2025-01-23 US disclosed
US-12178122-B2 Compound, composition including the same, liquid composition, and organic electroluminescent device SAMSUNG ELECTRONICS CO., LTD. (KR) 2024-12-24 US disclosed
EP-4448102-A1 NEW COMPOUND FOR THE TREATMENT AND PROPHYLAXIS OF INFECTIOUS DISEASES Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) 2024-10-23 EP disclosed
US-20240336573-A1 COMPOUND FOR THE TREATMENT AND PROPHYLAXIS OF INFECTIOUS DISEASES UNIVERSITEIT ANTWERPEN (BE) 2024-10-10 US disclosed
CN-116444499-B Phenylalanine derivative containing 4-quinazolinone and preparation method and application thereof 山东大学 2024-09-06 CN disclosed
WO-2014209034-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG LIFE SCIENCES LTD. (KR) 2014-12-31 WO disclosed
US-8637710-B2 Catalyst for cross-coupling reaction comprising unsubstituted or substituted bisphosphinobenzenes KYOTO UNIVERSITY (JP) 2014-01-28 US disclosed
US-8637710-B2 Catalyst for cross-coupling reaction comprising unsubstituted or substituted bisphosphinobenzenes KYOTO UNIVERSITY (JP) 2014-01-28 US disclosed
US-20110152523-A1 CATALYST FOR CROSS-COUPLING REACTION, AND PROCESS FOR PRODUCTION OF AROMATIC COMPOUND USING THE SAME KYOTO UNIVERSITY (JP) 2011-06-23 US disclosed
EP-1137641-B1 PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES SUMITOMO CHEMICAL CO (JP) 2004-11-10 EP disclosed
US-6500951-B1 RING CLOSING A CARBOXYLIC ACID DERIVATIVE IN PRESENCE OF A NITROGEN CONTAINING AROMATIC COMPOUND AND A BORON COMPOUND; HIGH YIELD AND PURITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-12-31 US disclosed
EP-1137641-A1 PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2001-10-04 EP disclosed
WO-2000034249-A1 PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12178122-B2 Compound, composition including the same, liquid composition, and organic electroluminescent device TERT, TELO2, POT1 LPL 1723/4885LIPG 2234/4885ROCK1 1743/4885
US-20240336573-A1 COMPOUND FOR THE TREATMENT AND PROPHYLAXIS OF INFECTIOUS DISEASES TLR1, TLR5, TLR4 LPL 803/4885LIPG 1286/4885ROCK1 3575/4885
US-20110152523-A1 CATALYST FOR CROSS-COUPLING REACTION, AND PROCESS FOR PRODUCTION OF AROMATIC COMPOUND USING THE SAME AHR, AR, HRH2 LPL 4860/4885LIPG 4876/4885ROCK1 2570/4885
US-20250026778-A1 GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR LGALS3, LGALS1, LGALS3BP LPL 1685/4885LIPG 1374/4885ROCK1 1037/4885
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells KCNN1, HCN4, KCNN2 LPL 4624/4885LIPG 4122/4885ROCK1 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.